Similis Bio Entered into a Development and License Agreement with Blau Farmaceutica to Co-Develop Four Biosimilar Programs
Shots:
- Similis Bio collaborated with Blau Farmacêutica for 4 biosimilar assets targeted indications in oncology, inflammation, and blood disorders
- Similis Bio uses its expertise and experience to support programs & provides additional treatment options for debilitating diseases patients & will be responsible to provide full processes and associated IP for tech transfer to Blau incl. cell lines, analytical data, and methodologies, and upstream/downstream processes
- Blau gets exclusive rights globally and intent to sell in America by itself and partner with local organizations in other regions & will be responsible for domestic development and seeking regulatory approval in Latin American markets
Ref: Businesswire | Image: Similis Bio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
